These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
192 related items for PubMed ID: 2747341
1. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers. Adamus WS, Heuer H, Meade CJ. Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):415-20. PubMed ID: 2747341 [Abstract] [Full Text] [Related]
2. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736. Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M. J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030 [Abstract] [Full Text] [Related]
3. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K. Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331 [Abstract] [Full Text] [Related]
4. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. Brecht HM, Adamus WS, Heuer HO, Birke FW, Kempe ER. Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613 [Abstract] [Full Text] [Related]
5. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. Casals-Stenzel J, Muacevic G, Weber KH. J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913 [Abstract] [Full Text] [Related]
6. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH. J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914 [Abstract] [Full Text] [Related]
7. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo. Yue TL, Rabinovici R, Farhat M, Feuerstein G. J Lipid Mediat; 1991 Dec; 3(1):13-26. PubMed ID: 1768837 [Abstract] [Full Text] [Related]
8. Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation. Adamus WS, Heuer H, Meade CJ, Frey G, Brecht HM. Eur J Clin Pharmacol; 1988 Dec; 35(3):237-40. PubMed ID: 3181277 [Abstract] [Full Text] [Related]
9. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086. Wilson DV, Eberhart SW, Robinson NE, Rice R, Gray PR. Am J Vet Res; 1993 Feb; 54(2):274-9. PubMed ID: 8430938 [Abstract] [Full Text] [Related]
10. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J. J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188 [Abstract] [Full Text] [Related]
11. Calcium-dependent synergistic interaction of platelet activating factor and epinephrine in human platelet aggregation. Saeed SA, Rasheed H. Acta Pharmacol Sin; 2003 Jan; 24(1):31-6. PubMed ID: 12511226 [Abstract] [Full Text] [Related]
12. Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086 in man. Hayes JP, Ridge SM, Griffith S, Barnes PJ, Chung KF. J Allergy Clin Immunol; 1991 Jul; 88(1):83-8. PubMed ID: 2071787 [Abstract] [Full Text] [Related]
13. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist. Rabinovici R, Yue TL, Farhat M, Smith EF, Esser KM, Slivjak M, Feuerstein G. J Pharmacol Exp Ther; 1990 Oct; 255(1):256-63. PubMed ID: 2213560 [Abstract] [Full Text] [Related]
14. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats. Akagi M, Nishioka E, Kanoh R, Tachibana M, Fukuishi N. Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165 [Abstract] [Full Text] [Related]
15. Safety, tolerability, and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects. Adamus WS, Heuer H, Meade CJ, Brecht HM. Clin Pharmacol Ther; 1989 Mar; 45(3):270-6. PubMed ID: 2920502 [Abstract] [Full Text] [Related]
16. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF. J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676 [Abstract] [Full Text] [Related]
17. Combined effect of Web 2086 (Paf antagonist) and ketoprofen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine. Bastos da Silva M, Herion F, Raskinet R, David JL, Gustin P, Lekeux P. Zentralbl Veterinarmed A; 1997 Apr; 44(2):65-71. PubMed ID: 9284631 [Abstract] [Full Text] [Related]
18. Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator. Hofmann B, Ostermann G, Hoffmann A, Klöcking HP, Kertscher HP. Biomed Biochim Acta; 1988 Apr; 47(10-11):S157-60. PubMed ID: 3248103 [Abstract] [Full Text] [Related]
19. Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologic changes induced by PAF inhalation in human beings. Adamus WS, Heuer HO, Meade CJ, Schilling JC. Clin Pharmacol Ther; 1990 Apr; 47(4):456-62. PubMed ID: 2328553 [Abstract] [Full Text] [Related]
20. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity. Castro-Faria-Neto HC, Martins MA, Silva PM, Bozza PT, Cruz HN, de Queiroz-Paulo M, Kaplan MA, Cordeiro RS. J Lipid Mediat; 1993 May; 7(1):1-9. PubMed ID: 8358020 [Abstract] [Full Text] [Related] Page: [Next] [New Search]